Treatment A + Treatment B + Treatment C

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
30
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms

Conditions

Vasomotor Symptoms

Trial Timeline

Nov 5, 2025 โ†’ Jan 14, 2026

About Treatment A + Treatment B + Treatment C

Treatment A + Treatment B + Treatment C is a phase 1 stage product being developed by Bayer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT07229404. Target conditions include Vasomotor Symptoms.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07229404Phase 1Completed

Competing Products

20 competing products in Vasomotor Symptoms

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
77
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
52
esomeprazole + placeboAstraZenecaPre-clinical
23
MK-6913 + 17-ฮฒ estradiol + Placebo to MK-6913 + Placebo to 17-ฮฒ estradiol + MK-6913 25 mgMerckPhase 2
52
Erenumab + PlaceboAmgenPhase 1
32
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
84
DVS-233 SRPfizerPhase 3
76
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
76
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
32
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
76
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
76
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
30
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
74
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
30
Elinzanetant (BAY3427080)BayerPhase 1
30
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
30
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
30
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
74
BAY3427080BayerPhase 1
30
Elinzanetant (BAY3427080) + RosuvastatinBayerPhase 1
30